Choosing and using Drosophila models to characterize modifiers of Huntington's disease.

HD (Huntington's disease) is a fatal inherited gain-of-function disorder caused by a polyQ (polyglutamine) expansion in the htt (huntingtin protein). Expression of mutant htt in model organisms is sufficient to recapitulate many of the cellular defects found in HD patients. Many groups have independently developed Drosophila models of HD, taking advantage of its rapid life cycle, carefully annotated genome and well-established molecular toolkits. Furthermore, unlike simpler models, Drosophila have a complex nervous system, displaying a range of carefully co-ordinated behaviours which offer an exquisitely sensitive readout of neuronal disruption. Measuring HD-associated changes in behaviour in Drosophila therefore offers a window into the earliest stages of HD, when therapeutic interventions might be particularly effective. The present review describes a number of recently developed Drosophila models of HD and offers practical guidance on the advantages and disadvantages of various experimental approaches that can be used to screen these models for modifiers of mutant htt-mediated toxicity.

[1]  G. Rubin,et al.  P element insertion-dependent gene activation in the Drosophila eye. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[2]  L. Cardon,et al.  Replication of twelve association studies for Huntington’s disease residual age of onset in large Venezuelan kindreds , 2006, Journal of Medical Genetics.

[3]  J. Olson,et al.  Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration , 2007, PLoS genetics.

[4]  M. MacDonald,et al.  Huntington's disease: the case for genetic modifiers , 2009, Genome Medicine.

[5]  J. Tower,et al.  Alteration of Drosophila life span using conditional, tissue-specific expression of transgenes triggered by doxycyline or RU486/Mifepristone , 2007, Experimental Gerontology.

[6]  J. Kramer,et al.  GAL4 causes developmental defects and apoptosis when expressed in the developing eye of Drosophila melanogaster. , 2003, Genetics and molecular research : GMR.

[7]  E. Wanker,et al.  Glial Cell Lineage Expression of Mutant Ataxin-1 and Huntingtin Induces Developmental and Late-Onset Neuronal Pathologies in Drosophila Models , 2009, PloS one.

[8]  Troy Zars,et al.  Learning and memory in Drosophila: behavior, genetics, and neural systems. , 2011, International review of neurobiology.

[9]  M. Miura,et al.  Aging causes distinct characteristics of polyglutamine amyloids in vivo , 2011, Genes to cells : devoted to molecular & cellular mechanisms.

[10]  J. Marsh,et al.  Fly models of Huntington's disease. , 2003, Human molecular genetics.

[11]  George R. Jackson,et al.  Neurodegenerative models in Drosophila: Polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis , 2010, Neurobiology of Disease.

[12]  É. Bourg,et al.  Hypergravity and Aging in Drosophila melanogaster , 1996 .

[13]  É. Le Bourg,et al.  Hypergravity and aging in Drosophila melanogaster. 5. Patterns of movement. , 1992, Gerontology.

[14]  H. Theisen,et al.  Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. , 2000, Human molecular genetics.

[15]  S. Benzer,et al.  Genetic suppression of polyglutamine toxicity in Drosophila. , 2000, Science.

[16]  P. Verstreken,et al.  Suppression of Neurodegeneration and Increased Neurotransmission Caused by Expanded Full-Length Huntingtin Accumulating in the Cytoplasm , 2008, Neuron.

[17]  M. Hayden,et al.  Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. , 2010, Human molecular genetics.

[18]  J. B. Duffy,et al.  GAL4 system in drosophila: A fly geneticist's swiss army knife , 2002, Genesis.

[19]  Karen Marder,et al.  Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. Rubin,et al.  Refinement of Tools for Targeted Gene Expression in Drosophila , 2010, Genetics.

[21]  S. Benzer,et al.  Suppression of polyglutamine toxicity by a Drosophila homolog of myeloid leukemia factor 1. , 2002, Human molecular genetics.

[22]  James E Bear,et al.  A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Myers,et al.  A putative Drosophila homolog of the Huntington's disease gene. , 1999, Human molecular genetics.

[24]  N. Perrimon,et al.  Exploiting position effects and the gypsy retrovirus insulator to engineer precisely expressed transgenes , 2008, Nature Genetics.

[25]  Susan Lindquist,et al.  Yeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or α-Synuclein , 2003, Science.

[26]  A. Tobin,et al.  A cell-based screen for drugs to treat Huntington's disease , 2004, Neurobiology of Disease.

[27]  Michele P Calos,et al.  Construction of transgenic Drosophila by using the site-specific integrase from phage phiC31. , 2004, Genetics.

[28]  I. Bezprozvanny,et al.  Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment. , 2011, Chemistry & biology.

[29]  G. Technau,et al.  The commonly used marker ELAV is transiently expressed in neuroblasts and glial cells in the Drosophila embryonic CNS , 2007, Developmental dynamics : an official publication of the American Association of Anatomists.

[30]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[31]  R. Greenspan.  A kinder, gentler genetic analysis of behavior: dissection gives way to modulation , 1997, Current Opinion in Neurobiology.

[32]  N. Perrimon,et al.  A Genomewide RNA Interference Screen for Modifiers of Aggregates Formation by Mutant Huntingtin in Drosophila , 2010, Genetics.

[33]  Iris Salecker,et al.  Polyglutamine-Expanded Human Huntingtin Transgenes Induce Degeneration of Drosophila Photoreceptor Neurons , 1998, Neuron.

[34]  N. Nukina,et al.  RNAi Screening in Drosophila Cells Identifies New Modifiers of Mutant Huntingtin Aggregation , 2009, PloS one.

[35]  W. Hillen,et al.  Tetracycline-inducible systems for Drosophila , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Ann-Shyn Chiang,et al.  Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Littleton,et al.  Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. MacDonald,et al.  Huntingtin: a single bait hooks many species , 1998, Current Opinion in Neurobiology.

[39]  P. Rørth.  Gal4 in the Drosophila female germline , 1998, Mechanisms of Development.

[40]  N. Perrimon,et al.  Inactivation of Drosophila Huntingtin affects long-term adult functioning and the pathogenesis of a Huntington’s disease model , 2009, Disease Models & Mechanisms.

[41]  Yanling Liu,et al.  A Genomic Response to the Yeast Transcription Factor GAL4 in Drosophila , 2008, Fly.

[42]  Jane S. Paulsen,et al.  A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. , 2003, American journal of human genetics.

[43]  Jane S. Paulsen,et al.  Genome-wide significance for a modifier of age at neurological onset in Huntington's Disease at 6q23-24: the HD MAPS study , 2006, BMC Medical Genetics.

[44]  N. Perrimon,et al.  Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. , 1993, Development.

[45]  J. Littleton,et al.  Huntingtin Aggregation Kinetics and Their Pathological Role in a Drosophila Huntington’s Disease Model , 2012, Genetics.

[46]  Matt Kaeberlein,et al.  Absence of effects of Sir2 over-expression on lifespan in C. elegans and Drosophila , 2011, Nature.

[47]  S. Zipursky,et al.  Inactivation of Drosophila Apaf-1 related killer suppresses formation of polyglutamine aggregates and blocks polyglutamine pathogenesis. , 2005, Human molecular genetics.

[48]  G. Rubin,et al.  Genetic transformation of Drosophila with transposable element vectors. , 1982, Science.

[49]  Pengyu Hong,et al.  High-Content Chemical and RNAi Screens for Suppressors of Neurotoxicity in a Huntington's Disease Model , 2011, PloS one.

[50]  M. MacDonald,et al.  Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease , 2003, American journal of medical genetics. Part A.

[51]  D. Housman,et al.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila , 2001, Nature.

[52]  M. Rose,et al.  Doxycycline-induced expression of sense and inverted-repeat constructs modulates phosphogluconate mutase (Pgm) gene expression in adult Drosophila melanogaster , 2002, Genome Biology.

[53]  Bassem A. Hassan,et al.  atonal Regulates Neurite Arborization but Does Not Act as a Proneural Gene in the Drosophila Brain , 2000, Neuron.

[54]  R. Schwarcz,et al.  The Kynurenine Pathway Modulates Neurodegeneration in a Drosophila Model of Huntington's Disease , 2011, Current Biology.

[55]  L. Cardon,et al.  Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds , 2008, Genetic epidemiology.